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Abstract: 
Background:  Outcomes in younger (<40 years) and elderly (≥70 years) patients with advanced 
biliary cancer (ABC) receiving palliative chemotherapy are unclear.  This study assessed 
outcomes in those receiving monotherapy or combination therapy in thirteen prospective 
systemic-therapy trials. 
Methods:  Multivariable analysis explored the impact of therapy on progression-free (PFS) and 
overall survival (OS) in two separate age cohort groups: <70 years and ≥70 years, and <40 years 
and ≥40 years. 
Results:  Overall, 1163 patients were recruited (Jan 1997-Dec 2013).  Median age of entire 
cohort: 63 years (range 23-85); 36 (3%) were <40, 260 (22%); ≥70.  Combination therapy was 
platinum-based in nine studies.  Among patients <40 and ≥70 years, 23 (64%) and 182 (70%) 
received combination therapy, respectively.  Median follow-up was 42 months (95%-CI 37-51).  
Median PFS for patients <40 and ≥40 years was 3.5 and 5.9 months (P=0.12), and OS was 10.8 
and 9.7 months, respectively (P=0.55).  Median PFS for those <70 and ≥70 years was 6.0 and 5.0 
months (P=0.53), and OS was 10.2 and 8.8 months, respectively (P=0.08).  For the entire cohort, 
PFS and OS were significantly better in those receiving combination therapy: Hazard Ratio 
[HR]-0.66, 95%-CI 0.58-0.76, P<0.0001 and HR-0.72, 95%-CI 0.63-0.82, P<0.0001, 
respectively; and in patients ≥70 years: HR-0.54 (95%-CI 0.38-0.77, P=0.001) and HR-0.60 
(95%-CI 0.43-0.85, P=0.004), respectively.  There was no evidence of interaction between age 
and treatment for PFS (P=0.58, P=0.66) or OS (P=0.18, P=0.75). 
Conclusions:  In ABC, younger patients are rare, and survival in elderly patients in receipt of 
systemic therapy for advanced disease, whether monotherapy or combination therapy, is similar 
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to that of non-elderly patients, therefore age alone should not influence decisions regarding 
treatment. 
Keywords: Biliary cancer, younger patients, elderly, systemic therapy, prospective trials. 
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Background: 
Biliary tract cancers are rare and encompass cholangiocarcinoma, referring to cancers arising in 
the intrahepatic, perihilar, or distal biliary tree, gallbladder cancer and carcinoma of the ampulla 
of Vater [1].  Combination treatment with cisplatin/gemcitabine is currently considered standard 
of care for the treatment of patients with advanced biliary cancer (ABC), following the results of 
the randomised-controlled phase 3 trial, ABC-02, which reported a progression-free (PFS) and 
overall survival (OS) benefit for this combination over gemcitabine alone in 410 patients with 
ABC [2].   
Comorbidities and age-related organ dysfunction are more often reported in elderly patients.  
There is often uncertainty regarding the benefits and risks of treatment in this subgroup [3-4], 
which in turn may lead to a reluctance to implement chemotherapy, and particularly combination 
therapy, in these patients. Consequently they tend to represent a minority of those enrolled in 
clinical trials.  There is thus less evidence to support treatment of elderly patients with cancer, 
who make up the majority of patients with this diagnosis. 
For the more common cancers such as lung [5-6] and colorectal cancer [7], there have been 
elderly-specific randomised-controlled trials and robust age-specific subgroup analyses of large 
studies, which provide guidance on treatment decisions in the clinical setting.  However, there is 
a dearth of such data for rarer tumours such as ABC. In a progressively-ageing population, 
outcomes in elderly patients with ABC receiving palliative chemotherapy are unclear and can be 
a challenging therapeutic scenario for oncologists. 
In addition, younger age may also influence outcomes in patients with a cancer diagnosis.  In 
patients aged ≤30 years with breast cancer referred for surgery, for example, it has been reported 
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that there is a greater chance of having an endocrine-unresponsive tumour and a significantly 
worse prognosis than those patients aged between 31 and 50 years [8].  It has also been described 
that younger patients (<40 years) with peripheral cholangiocarcinoma had a significantly worse 
survival rate than older patients who received surgical treatment [9].  However, information is 
lacking on the influence of age on the outcomes of younger patients receiving systemic therapy 
for ABC and so 40 years was chosen as age cut-off for further analysis based on publication by 
Yeh et al [9].   
The American Society of Clinical Oncology recently developed recommendations to improve 
evidence generation in older patients with cancer in response to a critical need identified by the 
Institute of Medicine [10]. Hence, the aim of this study was to assess outcomes (PFS and OS) of 
receipt of monotherapy versus combination therapy in younger (<40 years) and elderly patients 
(≥70 years) with ABC in ABC-02 and twelve other prospective trials of systemic therapy. 
Seventy years was chosen as the age cut-off for elderly patients in this study due to the 
exponential rise in the prevalence of age-related changes between 70-75 years, and that 
approximately 90% of people demonstrate clinical signs of ageing by the age of 70 [11]. 
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Methods: 
Individual patient data from eleven international first-line clinical trials, and two using targeted 
therapies (with one study including eleven and another nine patients who received one prior line 
of therapy), in ABC (The International Biliary Tract Cancer Collaborators provided approval for 
the use of this data) were accessed for analysis (Table 1) [2, 12-23].    All trials were approved 
by appropriate research ethics committees and regulatory authorities and conducted in 
accordance with the Declaration of Helsinki.  Baseline characteristics analysed included age, 
gender, Eastern Cooperative Oncology Group Performance Status (ECOG PS), disease stage 
(locally advanced versus metastatic), systemic therapy (monotherapy or combination). Site of 
primary (cholangiocarcinoma, gallbladder or ampulla of Vater), histology of tumour 
(adenocarcinoma versus other), previous therapy, haemoglobin, white blood cell, neutrophil 
count, and bilirubin were analysed and presented as part of a previous publication [24], where a 
model of neutrophils, disease stage, bilirubin, ECOG PS, haemoglobin, white blood cells, and 
gender were prognostic for PFS and OS, whereas age, site of primary, histology of tumour, 
previous therapy, and platelets were not [24].  Interrogation of those patients receiving 
combination cisplatin/gemcitabine has also been extensively analysed previously [24-25].  The 
association between baseline categorical variables and age was tested using the Chi-squared test. 
This study was an exploratory analysis based on available data.  Detection of a specific effect 
size (hazard ratio) was not the target, and so power calculations were not used, as detection of an 
intended hazard ratio was not required.  Progression-free survival [time from randomisation to 
progression or death, whichever happens first] and OS [time from randomisation to death] were 
analysed using Cox proportional hazards regression.  Multivariable analysis was employed to 
explore the impact of age and therapy (monotherapy versus combination) on PFS and OS in four 
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age cohorts; those <40 years (younger) versus ≥40 years and non-elderly (<70 years) versus 
elderly (≥70 years).  The multivariable model was adjusted for the following variables: gender, 
ECOG PS, disease stage, haemoglobin, white blood cell count, neutrophil count, and bilirubin. 
The Stata, version 14.1, statistical software package (Stata Corporation, College Station, Texas) 
was used to analyse the data. 
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Results: 
Patient characteristics 
Overall, 1163 patients were recruited (January 1997-December 2013).  Details on prospective 
studies included are contained within Table 1.  Complete demographic data for individual trials 
is available within respective publications [2, 12-23]. 
The baseline patient characteristics for all patients are detailed in Table 2. The median age of the 
entire cohort was 63 years (range 23-85); 36 (3%) were <40, 260 (22%) were ≥70 and 18 (2%) 
were ≥80 years.  Baseline characteristics/therapy received was balanced in all age cohorts (Table 
2).  Combination therapy was platinum-based in nine studies (N=679 [58%]). 
The median follow-up time for all patients was 42 months (95%-Confidence Interval [CI] 37-
51). 
Progression-free and Overall Survival 
The median PFS for the entire cohort [N=1163] was 5.8 months (95%-CI 5.5-6.2). 
The median PFS for patients aged <40 and ≥40 years was 3.5 (95%-CI 2.9-5.6) and 5.9 months 
(95%-CI 5.5-6.4) (P=0.12) and for those <70 and ≥70 years, 6.0 (95%-CI 5.5-6.4) and 5.0 
months (95%-CI 4.2-6.4), respectively (P=0.53). 
The 6-month PFS rate was 26% (95%-CI 13-41) and 49% (95%-CI 46-52) in the <40 and ≥40 
year old cohort, respectively.  The 6-month PFS rate was 50% (46-5253) and 45% (95%-CI 39-
51) in the <70 and ≥70 year old cohort, respectively. 
The median PFS in the entire cohort for those receiving monotherapy and combination therapy 
was 4.2 (95%-CI 3.7-5.1) and 6.5 months (95%-CI 6.0-7.1), respectively (P<0.0001) (Figure 1a). 
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The median OS for the entire cohort was 9.8 months (95%-CI 9.2-10.5). 
The median OS for patients <40 and ≥40 years was 10.8 (95%-CI 5.4-12.7) and 9.7 months 
(95%-CI 9.2-10.4) (P=0.55) and for patients <70 and ≥70 years, 10.2 (95%-CI 9.6-11.1) and 8.8 
months (95%-CI 7.9-9.6), respectively (P=0.08). 
The 6-month OS rate was 60% (95%-CI 42-74) and 71% (95%-CI 68-74) in the <40 and ≥40 
year old cohort respectively.  The 6-month OS rate was 72% (68-74) and 68% (95%-CI 61-73) in 
the <70 and ≥70 year old cohort, respectively. 
The median OS in the entire cohort for those receiving monotherapy and combination therapy 
was 8.1 (95%-CI 7.1-8.7) and 10.6 months (95%-CI 9.8-11.4), respectively (P<0.0001) (Figure 
1b).   
In the entire population, the PFS and OS were significantly better in those patients receiving 
combination therapy in the individual age groups; ≥40, <70 and ≥70 years, but not in those aged 
<40 years (Figure 2). 
Similarly, in a sub-analysis of those patients receiving the cisplatin/gemcitabine combination 
(N=297) versus those receiving gemcitabine alone (N=258), the PFS and OS were significantly 
better in those patients receiving combination therapy in the individual age groups; ≥40 (both 
P<0.001), <70 (P<0.001 and P=0.002 respectively) and ≥70 years (P=0.003 and P=0.014 
respectively), but not in those aged <40 years (P=0.71 and P=0.72 respectively). 
Prognostic factors 
Age was not prognostic for PFS or OS in those receiving monotherapy (P=0.49 and P=0.08 
respectively) or combination therapy (P=0.67 and P=0.27 respectively), and there was no 
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evidence of interaction between age and treatment (monotherapy and combination therapy) in the 
<40 and ≥40 years age groups for PFS (P=0.58) or OS (P=0.18) or in the <70 and ≥70 years age 
groups for PFS (P=0.66) or OS (P=0.75).  There was no evidence of an interaction between 
tumour location and age on PFS (Interaction with age model P value: Hilar: P=0.46, Gallbladder: 
P=0.33, Extrahepatic: P=0.49, Ampulla of Vater: P=0.20) or OS (Hilar: P=0.53, Gallbladder: 
P=0.99, Extrahepatic: P=0.60, Ampulla of Vater: P=0.56). 
In the overall population, on multivariable analysis, PFS was worse in those patients with 
metastatic disease versus those with locally advanced disease in those receiving monotherapy 
(Hazard Ratio [HR] 1.35, 95%-CI 0.99-1.83, P=0.06) and combination therapy (HR 1.42, 95%-
CI 1.16-1.75, P=0.001).  Overall survival was also worse in those patients with metastatic 
disease versus those with locally advanced disease in those receiving monotherapy (HR 1.54, 
95%-CI 1.12-2.12, P=0.01) and combination therapy (HR 1.41, 95%-CI 1.14-1.74, P=0.001). 
In patients <40 years, ECOG PS was prognostic for PFS and OS and in patients ≥40 years, stage 
was prognostic for PFS, and stage and ECOG PS were prognostic for OS (Table 3). 
In patients <70 years, stage and ECOG PS were prognostic for PFS and OS; and in patients ≥70 
years, they were prognostic for OS (Table 4). 
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Discussion: 
Information is lacking on outcomes of patients with a diagnosis of ABC who are <40 years 
receiving palliative chemotherapy, and as the global population ages, there is also an increasing 
focus on the need to evaluate treatment outcomes in older patients with cancer.  No prospective 
studies report on the efficacy and safety of palliative chemotherapy in younger patients with 
ABC and only a few studies; none prospective, have reported on efficacy and safety of palliative 
chemotherapy in elderly patients with ABC [26-28].  Although gemcitabine-platinum doublet 
therapy is now the most common standard therapeutic option for patients with ABC [2, 18], there 
may be resistance among physicians in general clinical practice to prescribe combination rather 
than monotherapy in an older population due to perceptions of potential increased toxicity and 
increased presence of comorbidities. 
Age was not prognostic for PFS or OS in those receiving monotherapy or combination therapy.  
Progression-free and OS in patients receiving combination versus monotherapy were statistically 
significantly better in those ≥40 years and in those <70 and ≥70 years in the entire population 
and in a sub-group analysis of those receiving the cisplatin/gemcitabine combination versus 
gemcitabine alone.  The small sample size in those patients <40 years precluded a significant 
outcome and may be associated with a relevant bias and so results may be of limited value in this 
subgroup.  Similar percentages of patients with locally advanced and metastatic disease were 
included within the <40 and ≥40 year subgroups, and so this would not account for results 
obtained.  No family history was reported in patient subgroups, but the life-time risk of bile duct 
cancers in patients with Lynch syndrome is only approximately 2% [29], and should not be 
relevant here.  Given that this was an international collaboration, this does highlight the rarity of 
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ABC in this age group, at least in those included in these prospective clinical trials for ABC [3%] 
[2, 12-23]. 
There were only eighteen patients aged ≥80 years, therefore meaningful subgroup analysis was 
not possible and the benefit of combination versus monotherapy remains unclear in this age 
cohort.  Eastern Cooperative Oncology Group PS was prognostic for OS in all of the four age 
cohorts and the presence of metastatic rather than locally advanced disease had an adverse 
prognostic effect on OS in those ≥40, <70 and ≥70 years, which is similar to findings from ABC-
02 [2]. 
Limitations of this study are lack of toxicity and comorbidity analysis, and consequently the cost 
of these toxicities and potential inpatient stays, to the elderly population, cannot be estimated.  
However, toxicity data and treatment duration have been published previously within individual 
manuscripts [2, 12-23], and it is unlikely that patients with significant comorbidities were 
included in these prospective studies due to clinical trial eligibility criteria. Of course, selection 
bias may then be inherent in prospective studies, but it has recently been reported in a large 
retrospective study that active therapy, when given, in older patients with ABC, is associated 
with similar survival benefits, irrespective of age [28].  It has also recently been reported that the 
survival advantage of cisplatin/gemcitabine compared to gemcitabine alone was not associated 
with an improvement or deterioration of quality of life in ABC-02 [30]. 
Another limiting factor of this analysis was the heterogeneity of the treatment given in the 
included series, but the OS data reported for monotherapy and combination therapy in patients 
with ABC is not dissimilar within this study to that reported in ABC-02, and the addition of 
chemotherapy or targeted therapy to the established ABC-02 regimen, or others, has not lead to 
significant improvements in survival to date [2, 12-23, 31].  The shorter PFS reported in the 
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current study in patients receiving monotherapy and combination therapy may be attributable to 
scanning interval variation.  In ABC-02, this was 12 weekly [2], whereas in Okusaka et al [18], 
imaging was performed every 6 weeks [18, 31]. 
Data on therapy given following completion of respective therapies is not available, but as OS in 
the different age cohorts was comparable, it is likely that patients included in these clinical trials 
were treated similarly on progression.  However, given the rarity of this diagnosis, this study was 
a significant effort to address the role of systemic therapy in those <40 and ≥70 years in thirteen 
prospective trials, five of which were randomised. 
Conclusions: 
In patients with ABC, cautious interpretation of data is required in relation to monotherapy 
versus combination therapy in those patients <40 years, due to the limited number of patients in 
this subgroup, and more study in this age cohort is necessary.  Other age-related co-variables 
such as primary sclerosing cholangitis and the potential presence of breast cancer susceptibility 
genes 1/2 (BRCA1/2) mutations may be enriched in those <40 years and may confound OS 
outcomes.  Survival in elderly patients (≥70 years) in receipt of systemic therapy for ABC is 
similar to that of non-elderly patients (<70 years), including significant benefit from combination 
therapies over monotherapy in the age strata ≥70 years similar to the overall population.  
Therefore, age alone should not dictate decisions on treatment, and thus elderly patient 
participation in clinical trials for ABC is appropriate, acknowledging that this study provides 
data on a clinical trial eligible population ≥70 years (e.g. very fit).  Comprehensive geriatric 
assessment tools [32-34], incorporating an understanding of older patient’s individual health 
profiles, their practical/social needs, and their wishes, rather than just their chronological age, 
need to be an integral component of the complicated decision-making processes when 
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deciphering which patients may benefit from potentially more toxic combination therapy, and 
should form a useful adjunct to future elderly patient-focused therapeutic trials with ABC. The 
utilisation of assessment tools to better predict tolerance and toxicity to chemotherapy should 
also be considered [35-37]. 
Abbreviations: 
ABC: advanced biliary cancer, CI: Confidence interval, ECOG PS: Eastern Cooperative 
Oncology Group Performance Status, HR: Hazard ratio, OS: Overall survival, PFS: Progression-
free survival,   
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Figure legends: 
Figure 1: Kaplan-Meier estimates of progression-free survival (a) and overall survival (b) in 
patients with advanced biliary tract cancer who received monotherapy versus combination 
therapy 
Figure 2: Hazard ratios (combination versus monotherapy) for progression-free and overall 
survival in different age cohorts 
(Adjusted for gender, Eastern Co-operative Oncology Group performance status, disease stage, 
haemoglobin, white blood cell count, neutrophil count, and bilirubin).  CI: confidence interval, 
PFS: progression-free survival, OS: overall survival. 
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Table 1: Details of prospective trials included 
Relevant 
publication 
N
a
 Age: Median 
(range) 
Phase Systemic Therapy 
Bekaii-Saab et 
al 2011 [12] 
28 56 (26-79) II, Non-randomised Selumetinib 
Goldstein et al 
2011 [13] 
50 59 (39-78) II, Non-randomised Gemcitabine/Cisplatin 
Jensen et al 
2012 [14] 
46 66 (37-80) II, Non-randomised Gemcitabine/Oxaliplatin/Panitumumab/
Capecitabine 
Lassen et al 
2011 [15] 
41 61 (35-75) II, Non-randomised Gemcitabine/Oxaliplatin/Capecitabine 
Malka et al 2014 
(BINGO) [16] 
150 62 (35-75) II, Randomised Gemcitabine/Oxaliplatin ± Cetuximab 
Moehler et al 
2014 (AIO) [17] 
102 64 (36-84) II, Randomised Gemcitabine ± Sorafenib 
Okusaka et al 
2010 (BT22) 
[18] 
83 66 (43-80) II, Randomised Gemcitabine ± Cisplatin 
Peck et al 2012 
[19] 
9 61 (31-83) II, Non-randomised Lapatinib 
Rao et al 2005 
[20] 
54 57 (36-76) III, Randomised 5-Fluorouracil/Etoposide/Leucovorin 
versus Epirubicin/Cisplatin/5-
Fluorouracil 
Riechelmann et 
al 2007 [21] 
75 61 (37-84) II, Non-randomised Gemcitabine/Capecitabine 
Ferraro et al 
2016 (TACTIC) 
[22] 
48 64 (40-82) II, Non-randomised Gemcitabine/Cisplatin/Panitumumab 
Valle et al 2010 
(ABC-02) [2] 
410 63 (23-85) III, Randomised Gemcitabine ± Cisplatin 
Wagner et al 
2009 [23] 
72 62 (36-80) II, Non-randomised Gemcitabine/Oxaliplatin/5-Fluorouracil 
a
Due to non-availability of some data, 5 patients were not included in overall analysis. 
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Table 2: Distribution of baseline characteristics by age group
a
 
 Covariate <40 years 
Total 
N=36 
N (%) 
≥40 years 
Total 
N=1127 
N (%) 
P-
value
b
 
<70 years 
Total 
N=903 
N (%) 
≥70 years 
Total 
N=260 
N (%) 
P-
value
b
 
Gender Female 
Male 
16  (44) 
20 (56) 
597 (53) 
530 (47) 
0.31 482 (53) 
421 (47) 
131 (50) 
129 (50) 
0.39 
ECOG 
performance 
status 
0 
1 
2 
Not available 
10 (28) 
16 (44) 
4 (11) 
6 (17) 
350 (31) 
572 (51) 
81 (7) 
124 (11) 
0.59 285 (32) 
455 (50) 
60 (7) 
103 (11) 
75 (29) 
133 (51) 
25 (10) 
27 (10) 
0.24 
Disease  
Stage 
Locally advanced  
Metastatic  
Not available 
9 (25) 
27 (75) 
0 (0) 
295 (26) 
800 (71) 
32 (3) 
0.80 233 (26) 
652 (72) 
18 (2) 
71 (27) 
175 (67) 
14 (5) 
0.43 
Treatment Combination 
Monotherapy 
Not available 
23 (64) 
12 (33) 
1 (3) 
809 (72) 
301 (27) 
17 (2) 
0.20 650 (72) 
239 (26) 
14 (2) 
182 (70) 
74 (28) 
4 (2) 
0.48 
 
aDue to rounding, all percentages in Table 2 may not equal 100%.  bChi-squared test; performed 
excluding the category “not available”. 
ECOG performance status: Eastern Cooperative Oncology Group Performance Status.   
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Table 3: Multivariable analysis for progression-free and overall survival (<40 and ≥40 years)a 
 Covariate PFS 
<40 years 
PFS 
≥40 years 
OS 
<40 years 
OS 
≥40 years 
Gender 
(reference; 
female) 
Female vs 
Male 
 
HR  0.41 
(95% CI 
0.13-1.33, 
P=0.14) 
HR 1.02 
(95% CI 
0.88-1.18, 
P=0.81) 
HR 1.11 (95% 
CI 0.38-3.20, 
P=0.85) 
HR 1.14 
(95% CI 
0.97-1.32, 
P=0.10) 
ECOG 
performance 
status 
(reference; 0) 
0 vs 1 
 
 
0 vs 2 
HR 4.94 
(95% CI 
1.13-21.52) 
 
HR 15.89 
(95% CI 
2.19-115.33) 
[P=0.01] 
HR 1.05 
(95% CI 
0.89-1.23) 
 
HR 1.39 
(95% CI 
1.04-1.85) 
[P=0.10] 
HR 3.59 
(95%CI 0.79-
16.37) 
 
HR 113.11 
(95% CI 7.99-
1600.53) 
[P=0.001] 
HR 1.02 
(95%CI 0.86-
1.20) 
 
HR 1.87 
(95% CI 
1.40-2.50) 
[P=0.0002] 
Disease stage 
(reference; 
locally 
advanced) 
Locally 
advanced vs 
Metastatic 
 
HR 3.17 
(95% CI 
0.73-13.77, 
P=0.12) 
HR 1.38 
(95% CI 
1.17-1.64, 
P<0.001) 
HR 4.91 (95% 
CI 0.77-31.07, 
P=0.09) 
HR 1.40 
(95% CI 
1.18-1.68, 
P<0.001) 
 
a
The multivariable model was adjusted for the following variables; treatment, haemoglobin, 
white blood cell count, neutrophil count, and bilirubin. 
PFS: Progression-free survival, OS: Overall survival, ECOG PS: Eastern Cooperative Oncology 
Group Performance Status. 
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Table 4: Multivariable analysis for progression-free and overall survival (<70 and ≥70 years)a 
 Covariate PFS 
<70 years 
PFS 
≥70 years 
OS 
<70 years 
OS 
≥70 years 
Gender 
(reference; 
female) 
Female vs 
Male 
 
HR  1.00 
(95% CI 
0.84-1.18, 
P=0.98) 
HR 1.14 
(95% CI 
0.83-1.56, 
P=0.42) 
HR 1.12 
(95% CI 
0.94-1.33, 
P=0.22) 
HR 1.33 
(95% CI 
0.97-1.84, 
P=0.08) 
ECOG 
performance 
status 
(reference; 0) 
0 vs 1 
 
 
0 vs 2 
HR 1.10 
(95%CI 
0.92-1.32) 
 
HR 1.58 
(95%CI 
1.13-2.20) 
[P=0.04] 
HR 0.86 
(95%CI 
0.60-1.24) 
 
HR 1.03 
(95%CI 
0.58-1.83) 
[P=0.65] 
HR 1.08 
(95%CI 
0.90-1.31) 
 
HR 2.02 
(95%CI 
1.45-2.82) 
[P=0.001] 
HR 0.81 
(95%CI 
0.57-1.16) 
 
HR 1.84 
(95%CI 
1.03-3.28) 
[P=0.02] 
Disease stage 
(reference; 
locally 
advanced) 
Locally 
advanced vs 
Metastatic 
 
HR 1.46 
(95%CI 
1.20-1.78, 
P<0.001) 
HR 1.21 
(95%CI 
0.86-1.69, 
P=0.28) 
HR 1.48 
(95%CI 
1.20-1.82, 
P<0.001) 
HR 1.49 
(95%CI 
1.05-2.12, 
P=0.03) 
 
a
The multivariable model was adjusted for the following variables; treatment, haemoglobin, 
white blood cell count, neutrophil count, and bilirubin. 
PFS: Progression-free survival, OS: Overall survival, ECOG PS: Eastern Cooperative Oncology 
Group Performance Status. 
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